journal article·2025-08-20

Drug-Free Approach to Regulate Undruggable Proto-Oncogene MYC Using Biomimetic Porous Nanoparticles for Cancer Immunotherapy

Emilia Happonen, Yijing Dang, Jiajia Wang, Silja Saarela, Minna Sivonen, Mohammed Zakir, Milla-Iida Laari, Yiannis Constantinou, Konstantin Tamarov, Henri Hakkarainen, Ahmed Bisher Montaser, Henri Leinonen, Jenni Küblbeck, Tiit Örd, Mari Taipale, Minna Kaikkonen, Ruixian Liu, Juha Klefström, Haijun Yu, Zhiai Xu, Vesa-Pekka Lehto, Wujun Xu

ACS Applied Materials & Interfaces· Volume 17· Issue 33
Publisher page

Abstract

A proto-oncogene MYC plays a crucial role in controlling immune response, but as of today, it is undruggable. Some MYC inhibitors are under testing; nevertheless, they have low efficacy and severe toxicity. Up to now, the use of a drug-free approach to regulate MYC has been rarely investigated. The present study aims to identify the potential of drug-free photothermal therapy (PTT) in regulating MYC. Herein, biomimetic black porous silicon (BPSi) nanoparticles (NPs) were prepared via a novel self-templated Na-K alloy reduction method and then coated with a cancer cell membrane and polyethylene glycol. These NPs have efficient photothermal conversion, good biocompatibility, and homotypic tumor targeting. The results indicated that BPSi-based PTT could efficiently regulate MYC by tuning temperatures. However, only PTT at 50 °C could successfully inhibit MYC, while PTT at 46 °C upregulated MYC. Mechanism studies revealed that MYC inhibition was achieved via the downregulation of 'MYC Targets V1', and MAPK and JAK-STAT signaling pathways were involved. Finally, tumor-targeted PTT activated robust cancer immunotherapy by MYC inhibition and efficiently prevented tumor growth without significant toxicity in vivo. The present study highlights the potential of a drug-free approach to regulate MYC for more potent cancer immunotherapy.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Immune cells in cancer · Immunotherapy and Immune Responses

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Technical Physics

University of Eastern Finland

School of Chemistry and Molecular Engineering

East China Normal University

Department of Environmental and Biological Sciences

School of Pharmacy

A.I. Virtanen Institute for Molecular Sciences

Cancer Cell Circuitry Laboratory, Translational Cancer Medicine

University of Helsinki

Finnish Cancer Institute, Helsinki, Finland & FICAN South

Helsinki University Hospital

Department of Cell & Tissue Biology

University of California

State Key Laboratory of Drug Research and Center of Pharmaceutics

Shanghai Institute of Materia Medica, Chinese Academy of Sciences

Funding

Research Council of Finland · Sy?p?s??ti? · National Natural Science Foundation of China · Suomen Kulttuurirahasto

References (56)

Show source-provided references
1. 10.1038/s41523-022-00468-010.1038/s41523-022-00468-0 ↗
2. 10.1056/NEJMoa202848510.1056/NEJMoa2028485 ↗
3. 10.1056/NEJMoa180961510.1056/NEJMoa1809615 ↗
4. 10.1038/s41423-020-0488-610.1038/s41423-020-0488-6 ↗
5. 10.1038/s41467-022-34000-610.1038/s41467-022-34000-6 ↗
6. 10.1038/s41420-023-01403-310.1038/s41420-023-01403-3 ↗
7. 10.3390/ijms2120771010.3390/ijms21207710 ↗
8. 10.1038/s41467-022-31238-y10.1038/s41467-022-31238-y ↗
9. 10.1016/j.ccell.2019.10.00110.1016/j.ccell.2019.10.001 ↗
10. 10.1038/sj.onc.120219910.1038/sj.onc.1202199 ↗
11. 10.1038/nature0950410.1038/nature09504 ↗
12. 10.1016/j.bioorg.2020.10386610.1016/j.bioorg.2020.103866 ↗
13. 10.1158/1535-7163.MCT-18-102310.1158/1535-7163.MCT-18-1023 ↗
14. 10.1182/blood-2004-03-115310.1182/blood-2004-03-1153 ↗
15. 10.1002/advs.20220173410.1002/advs.202201734 ↗
16. 10.1038/nrc338010.1038/nrc3380 ↗
17. 10.1038/nm162210.1038/nm1622 ↗
18. 10.4049/jimmunol.173.1.30710.4049/jimmunol.173.1.307 ↗
19. 10.1038/nature0829610.1038/nature08296 ↗
20. 10.1038/nm.202810.1038/nm.2028 ↗
21. 10.1016/j.cell.2005.08.03210.1016/j.cell.2005.08.032 ↗
22. 10.1038/nri.2017.910.1038/nri.2017.9 ↗
23. 10.1021/acsnano.9b0604010.1021/acsnano.9b06040 ↗
24. 10.1002/adtp.20200020710.1002/adtp.202000207 ↗
25. 10.1002/smll.20180067810.1002/smll.201800678 ↗
26. 10.1053/j.tvir.2013.08.00210.1053/j.tvir.2013.08.002 ↗
27. 10.1016/j.matdes.2022.11039110.1016/j.matdes.2022.110391 ↗
28. 10.1016/j.actbio.2022.08.07310.1016/j.actbio.2022.08.073 ↗
29. 10.1021/acsami.9b1884410.1021/acsami.9b18844 ↗
30. 10.1021/acsami.2c0801310.1021/acsami.2c08013 ↗
31. 10.1038/s41467-022-33889-310.1038/s41467-022-33889-3 ↗
32. 10.1038/s41467-021-26052-x10.1038/s41467-021-26052-x ↗
33. 10.1016/j.ijpharm.2023.12376410.1016/j.ijpharm.2023.123764 ↗
34. Tamarov K. · Naitsok/Controlled-Ptt: Controlled PTT 2.0.4 · 2023
35. 10.1016/0360-3016(84)90379-110.1016/0360-3016(84)90379-1 ↗
36. 10.1016/j.ijpharm.2020.11965710.1016/j.ijpharm.2020.119657 ↗
37. 10.7554/eLife.5942210.7554/eLife.59422 ↗
38. 10.1038/nmeth.208910.1038/nmeth.2089 ↗
39. 10.1038/s41587-020-0439-x10.1038/s41587-020-0439-x ↗
40. 10.1093/bioinformatics/bts63510.1093/bioinformatics/bts635 ↗
41. 10.1038/nmeth.419710.1038/nmeth.4197 ↗
42. 10.1093/bioinformatics/btp61610.1093/bioinformatics/btp616 ↗
43. 10.1186/s13059-014-0550-810.1186/s13059-014-0550-8 ↗
44. 10.1101/06001210.1101/060012 ↗
45. 10.1016/j.cels.2015.12.00410.1016/j.cels.2015.12.004 ↗
46. 10.1038/s41596-018-0082-x10.1038/s41596-018-0082-x ↗
47. 10.1038/s41592-019-0638-x10.1038/s41592-019-0638-x ↗
48. 10.1074/mcp.M113.03159110.1074/mcp.M113.031591 ↗
49. 10.1039/b808500e10.1039/b808500e ↗
50. 10.1021/acsami.8b0455710.1021/acsami.8b04557 ↗
51. 10.1039/D2CS00479H10.1039/D2CS00479H ↗
52. 10.1158/2159-8290.CD-16-143910.1158/2159-8290.CD-16-1439 ↗
53. 10.1158/0008-5472.CAN-04-431610.1158/0008-5472.CAN-04-4316 ↗
54. 10.1158/1078-0432.CCR-11-322510.1158/1078-0432.CCR-11-3225 ↗
55. 10.1039/C8RA08472F10.1039/C8RA08472F ↗
56. 10.1039/C4NR00708E10.1039/C4NR00708E ↗